Adult Peritoneal Dialysis-Related Peritonitis Treatment Recommendations: 2000 Update

Aflaiw A. , Vas S. , Oreopoulos D.G. Peritonitis in patients on automated peritoneal dialysis. Contrib Nephrol 1999; 129: 213–28.

Alfa M.J. , Degagne P. , Olson N. , Harding G.K. Improved detection of bacterial growth in continuous ambulatory peritoneal dialysis effluent by use of BacT/Alert FAN bottles. J Clin Microbiol 1997; 35: 862–6.

Amyes S.G. The rise in bacterial resistance is partly because there have been no new classes of antibiotics since the 1960s. BMJ 2000; 320: 199–200.

Bailie G.R. , Eisele G. Pharmacokinetic issues in the treatment of continuous ambulatory peritoneal dialysis-associated peritonitis. J Antimicrob Chemother 1995; 35: 563–7.

Barclay M.L. , Kirkpatrick C.M. , Begg E.J. Once daily aminoglycoside therapy. Is it less toxic than multiple daily doses and how should it be monitored? Clin Pharmacokinet 1999; 36: 89–98.

Barza M. , Ioannidis J.P.A. , Cappelleri J.C. , Lau J. Single or multiple daily doses of aminoglycosides: A meta-analysis. BMJ 1996; 312: 338–45.

Bernardini J. , Piraino B. , Holley J. , Johnston J.R. , Lutes R. A randomized trial of Staphylococcus aureus prophylaxis in peritoneal dialysis patients: Mupirocin calcium ointment 2% applied to the exit site versus cyclic oral rifampin. Am J Kidney Dis 1996; 27: 695–700.

Buring J.E. , Evans D.A. , Mayrent S.L. , Rosner B. , Colton T. , Hennekens C.H. Randomized trials of amino-glycoside antibiotics: Quantitative overview. Rev Infect Dis 1988; 10: 951.

Chan M.K. , Chan P.C.K. , Cheng I.P.K. , Chan C.Y. , Ng W.S. Pseudomonas peritonitis in CAPD patients: Characteristics and outcome of treatment. Nephrol Dial Transplant 1989; 4: 814–17.

Cheng I.K.P. , Fang G.X. , Chan T.M. , Chan P.C. , Chan M.K. Fungal peritonitis complicating peritoneal dialysis: Report of 27 cases and review of treatment. Q J Med 1989; 71: 407–16.

Churchill D.N. , Taylor D.W. , Vas S.I. , Oreopoulos D.G. , Kettcher K.B. , Fenton S.S.A. Peritonitis in continuous ambulatory peritoneal dialysis (CAPD): A multi-centre randomized clinical trial comparing the Y connector disinfectant system to standard systems. Perit Dial Int 1989; 9: 159–63.

Demotes–Mainard F. , Vincon G. , Ragnaud J.M. , Morlat P. , Bannwarth B. , Dangoumau J. Pharmacokinetics of intravenous and intraperitoneal ceftazidime in continuous ambulatory peritoneal dialysis. J Clin Pharmacol 1993; 33: 475–9.

Dumler F. , Gottschling L. , Umstead G. , Wilson J.M. Intermittent intraperitoneal ceftazidime dosing in end-stage renal disease. ASAIO J 1998; 44: M411–M414.

Flanigan M.J. , Hochstetler L.A. , Langholdt D. , Lim V.S. Continuous ambulatory peritoneal dialysis catheter infections: Diagnosis and management. Perit Dial Int 1994; 14: 248–54.

Gilbert D.N. Once-daily aminoglycoside therapy. Antimicrob Agents Chemother 1991; 399–405.

Govaerts P.J. , Claes J. , Van De Heyning P.H. , Jorens P.G. , Marquet J. , De Broe M.E. Aminoglycoside-induced ototoxicity. Toxicol Lett 1990; 52: 227–51.

Grabe D.W. , Bailie G.R. , Eisele G. , Frye R.F. Pharmacokinetics of intermittent intraperitoneal ceftazidime. Am J Kidney Dis 1999; 33: 111–17.

Gupta B. , Bernardini J. , Piraino B. Peritonitis associated with exit site and tunnel infections. Am J Kidney Dis 1996; 28: 415–19.

Harro C. , Braden G.L. , Morris A.B. , Lipkowitz G.S. , Madden R.L. Failure to cure Mycobacterium gordonae peritonitis associated with continuous ambulatory peritoneal dialysis. Clin Infect Dis 1997; 24: 955–7.

Innes A. , Burden R.P. , Finch R.G. , Morgan A.G. Treatment of resistant peritonitis in continuous ambulatory peritoneal dialysis with intraperitoneal urokinase: A double blind trial. Nephrol Dial Transplant 1994; 9: 797–9.

Keane W.F. , Vas S.I. Peritonitis. In: Gokal R. , Nolph K.D. , eds. The textbook of peritoneal dialysis, 4th ed. Dordrecht: Kluwer Academic, 1994: 473–501.

Koopmans J.G. , Boeschoten E.W. , Pannekeet M.M. , Betjes M.G.H. , Zemel D. , Kuijper E.J. Impaired initial cell reaction in CAPD-related peritonitis. Perit Dial Int 1996; 16(Suppl 1): S362–7.

Kuizon B. , Melocoton T.L. , Holloway M. , Ingles S. , Jing H.E. , Fonkalsrud E.W. Infectious and catheter-related complications in pediatric patients treated with peritoneal dialysis at a single institution. Pediatri Nephrol 1995; 9(Suppl): S12–17.

Locatelli A. , Quiroga M.A. , De Bendetti L. , Gomez M. , Barone R. , Barron M.C. Treatment of recurrent and resistant CAPD peritonitis by temporary withdrawal of peritoneal dialysis without removal of the catheter. Adv Perit Dial 1995; 11: 176–8.

Lomaestro B.M. , Bailie G.R. Absorption interactions with fluoroquinolones: 1995 update. Drug Saf 1995; 12: 314–37.

Low C.L. , Bailie G.R. , Evans A. , Eisele G. , Venezia R.A. Pharmacokinetics of once-daily IP gentamicin in CAPD patients. Perit Dial Int 1996; 16: 379–84.

Lui S.L. , Lo C.Y. , Choy B.Y. , Chan T.M. , Lo W.K. , Cheng I.K. Optimal treatment and long-term outcome of tuberculous peritonitis complicating continuous ambulatory peritoneal dialysis. Am J Kidney Dis 1996; 28: 747–51.

Luzar M.A. , Brown C.B. , Balf D. , Hill L. , Issad B. , Monnier B. Exit-site care and exit-site infection in CAPD: Results of a randomized multicenter trial. Perit Dial Int 1990; 10: 25–9.

Lye W.C. , van der Straaten J.C. , Leong S.O. , Sivaraman P. , Tan S.H. , Tan C.C. Once-daily intraperitoneal gentamicin is effective therapy for gram-negative CAPD peritonitis. Perit Dial Int 1999; 19: 357–60.

Manley H.J. , Bailie G.R. , Asher R.D. , Eisele G. , Frye R.F. Pharmacokinetics of intermittent intraperitoneal cefazolin in continuous ambulatory peritoneal dialysis patients. Perit Dial Int 1999; 19: 65–70.

Manley H.J. , Bailie G.R. , Frye R.F. , Hess L.D. , McGoldrick M.D. Pharmacokinetics of intermittent intravenous cefazolin and tobramycin in patients treated with automated PD. J Am Soc Nephrol 2000; 11: 1310–16.

Manley H.J. , Bailie G.R. , Neumann M. Antibiogram development for an outpatient hemodialysis center. Am J Health Syst Pharm 2000, 35: 251–3.

Millikin S.P. , Matzke G.R. , Keane W.F. Antimicrobial treatment of peritonitis associated with continuous ambulatory peritoneal dialysis. Perit Dial Int 1991; 11: 252–60.

Pagniez D.C. , MacNamara E. , Fortin F. , Delvallez L. , Fruchart A. , Dequiedt P. Withdrawal of continuous ambulatory peritoneal dialysis to treat mild peritonitis. BMJ 1988; 297: 1174–5.

Recommendations for preventing the spread of vancomycin resistance: recommendations of the Hospital Infection Control Practices Advisory Committee (HICPAC). MMWR 44 (RR12), 1995. Available from: URL: http://aepo-xdv-www.epo.cdc.gov/wonder/prevguid/m0039349/m0039349.htm

Sewell D.L. , Golper T.A. , Hulman P.B. , Thomas C.M. , West L.M. , Kubey W.Y. Comparison of large volume culture to other methods for isolation of micro-organisms from dialysate. Perit Dial Int 1990; 10: 49–52.

Shemin D. , Maaz D. , St. Pierre D , Kahn SI , Chazan JA. Effect of aminoglycoside use on residual renal function in peritoneal dialysis patients. Am J Kidney Dis 1999; 34: 14–20.

Smith T.L. , Pearson M.L. , Wilcox K.R. , Cruz C. , Lancaster M.V. , Robinson–Dunn B. Emergence of vancomycin resistance in Staphylococcus aureus. Glycopeptide-Intermediate Staphylococcus Aureus Working Group. N Engl J Med 1999; 340: 493–501.

Swartz R. , Messana J. , Reynolds J. , Ranjit U. Simultaneous catheter replacement and removal in refractory peritoneal dialysis infections. Kidney Int 1991; 40: 1160–5.

Swartz R.D. , Messana J.M. Simultaneous catheter removal and replacement in peritoneal dialysis infections: Update and current recommendations. Adv Perit Dial 1999; 15: 205–8.

The Mupirocin Study Group. Nasal mupirocin prevents Staphylococcus aureus exit site infection during peritoneal dialysis. J Am Soc Nephrol 1996; 11: 2403–8.

Tranæus A. , Heimbürger O. , Lindholm B. Peritonitis during continuous ambulatory peritoneal dialysis (CAPD): Risk factors, clinical severity, and pathogenetic aspects. Perit Dial Int 1988; 8: 253–63.

Troidle L. , Gorban–Brennan N. , Klinger A. , Finkelstein F. Once-daily intraperitoneal cefazolin and oral ciprofloxacin as empiric therapy for the treatment of peritonitis. Adv Perit Dial 1999; 15: 213–16.

Van Biesen W. , Vanholder R. , Vogelaers D. , Peleman R. , Verschraegen G. , Vijt D. The need for a center-tailored treatment protocol for peritonitis. Perit Dial Int 1998; 18: 274–81.

Van Rie A. , Warren R. , Richardson M. , Victor T.C. , Gie R.P. , Enarson D.A. Exogenous reinfection as a cause of recurrent tuberculosis after curative treatment. N Engl J Med 1999; 341: 1174–9.

Vas S.I. Renaissance of tuberculosis in the 1990s: Lesson for the nephrologist. Perit Dial Int 1994; 14: 209–14.

Vas S. , Bargman J. , Oreopoulos D.G. Treatment in PD patients of peritonitis caused by gram-positive organisms with single daily dose of antibiotics. Perit Dial Int 1997; 17: 91–4.

Vychytil A. , Lorenz M. , Schneider B. , Horl W.H. , Haag– Weber M. New strategies to prevent Staphylococcus aureus infections in peritoneal dialysis patients. J Am Soc Nephrol 1998; 9: 669–76.

White R. , Abreo K. , Flanagan R. , Gadallah M. , Krane K. , el-Shahawy M. Nontuberculous mycobacterial infections in continuous ambulatory peritoneal dialysis patients. Am J Kidney Dis 1993; 22: 581–7.

Williams A.J. , Boeltis I. , Johnson B.F. , Raftery A.T. , Cohen G.L. , Moorhead P.J. Tenckhoff catheter replacement or intraperitoneal urokinase: A randomised trial in the management of recurrent continuous ambulatory peritoneal dialysis (CAPD) peritonitis. Perit Dial Int 1989; 9: 65–7.

Zimmerman S.W. , Ahrens E. , Johnson C.A. , Craig W. , Leggett J. , O'Brien M. Randomized controlled trial of prophylactic rifampin for peritoneal dialysis related infections. Am J Kidney Dis 1991; 18: 225–31.